XBiotech Stock (NASDAQ:XBIT)
Previous Close
$3.18
52W Range
$2.65 - $9.45
50D Avg
$3.21
200D Avg
$5.50
Market Cap
$90.24M
Avg Vol (3M)
$52.38K
Beta
1.28
Div Yield
-
XBIT Company Profile
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
XBIT Performance
Peer Comparison
| Ticker | Company |
|---|---|
| TSVT | 2seventy bio, Inc. |
| KZR | Kezar Life Sciences, Inc. |
| CCCC | C4 Therapeutics, Inc. |
| KRON | Kronos Bio, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| ELDN | Eledon Pharmaceuticals, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| PASG | Passage Bio, Inc. |
| ERAS | Erasca, Inc. |
| ABSI | Absci Corporation |
| XFOR | X4 Pharmaceuticals, Inc. |
| REPL | Replimune Group, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| PHAT | Phathom Pharmaceuticals, Inc. |
| GBIO | Generation Bio Co. |
| INZY | Inozyme Pharma, Inc. |
| ADVM | Adverum Biotechnologies, Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |